98 results about "Hepatocellular necrosis" patented technology

This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

The present invention provides a therapeutic agent for acute liver failure containing a hepatocyte growth factor (HGF), particularly an agent for treating fulminant hepatitis or late onset hepatic failure or suppression of progression of acute liver failure without hepatic coma to fulminant hepatitis or late onset hepatic failure. The present invention also provides a method for evaluating the efficacy of HGF including measuring the amount of α-fetoprotein (liver regeneration biomarker) and/or soluble Fas (anti-apoptotic biomarker) in a sample obtained from a liver injury patient administered with HGF.

The invention discloses application of peripheral blood mononuclear cell activation inhibitors to preparing a medicine for treating and/or preventing acute hepatic failure, and further provides the medicine for treating and/or preventing the acute hepatic failure. The medicine is a preparation, the peripheral blood mononuclear cell activation inhibitors are used as active substances for the preparation, and pharmacologically acceptable excipients or auxiliary components are added into the peripheral blood mononuclear cell activation inhibitors to prepare the preparation. The application and the medicine have the advantages that the fact that activation of mononuclear cells can be effectively inhibited is proved, accordingly, acute hepatic injury can be effectively treated and prevented, a novel option can be provided for clinically treating the acute hepatic injury, and the medicine has an excellent application prospect.

The invention discloses a medicine composition with acetylcysteine and medical application of the medicine composition. The medicine composition with acetylcysteine contains clenbuterol hydrochloride and a natural product compound (I) which adopts a novel structure; when acetylcysteine and the compound (I) work independently, the effects of reducing serum transaminase, bilirubin and urea nitrogen contents of liver damaged animals can be achieved, jaundice and renal dysfunction are relieved, and the toxin content of plasma can be reduced; when acetylcysteine and the compound (I) are combined, the pharmacologic action is more obvious, and the medicine composition can be prepared into a medicine for treating acute liver failure; compared with the prior art, the medicine composition disclosed by the invention has outstanding substantive features and a remarkable progress.

The invention belongs to the field of biomedicine and disease diagnosis and particularly relates to application of osteopontin in the preparation or screening of diagnostic reagents for acute-on-chronic liver failure. It is disclosed herein for the first time that osteopontin can act as a biomarker for distinguishing acute-on-chronic liver failure (with diagnostic effect up to 0.9454), significantly higher than M30 (0.7167), M65 (0.8319) and M30/M65 (0.8100), and almost flush with clinically common index MELD (model for end-stage liver disease) (0.9317).

The invention discloses new application of sodium copper chlorophyllin to preparation of medicines for treating liver disease. Acute liver failure is caused by severe liver damage due to various factors, and can lead to acute necrosis and apoptosis of liver cells to show a group of clinical syndromes mainly represented by disturbances of blood coagulation, jaundice, hepatic encephalopathy, ascites and the like, and moreover, inflammatory response, particularly proinflammatory factors in a liver, plays a key role in incidence, deterioration and cure of the disease, so that slowing the inflammatory response can be one of approaches for adjuvant therapy of acute liver failure. Sodium copper chlorophyllin provided by the invention can inhibit interleukin-1 and interleukin-6 in liver tissues, as well as tumor necrosis factor alpha in the liver tissues. Experiments show that sodium copper chlorophyllin can be used to preparation of the medicines for treating liver disease.

The invention relates to a method for inducing a chronic and acute liver failure mouse model, in particular to a method for inducing the chronic and acute liver failure mouse model by using carbon tetrachloride, which comprises the following steps of: a grouping method is characterized by randomly and averagely dividing Balb/c inbred line mice into a model group and a control group; an administration method is characterized by diluting carbon tetrachloride to concentrations of 10% and 50% by using olive oil, continuously injecting 10% carbon tetrachloride into the abdominal cavity of a mouse in the model group according to 5-8ml/kg body weight, administrating twice a week, and continuously administrating for 8 weeks; after 8 weeks, injecting the 50% carbon tetrachloride into the abdominalcavity once according to 5-8 ml/kg body weight; and a detection method is characterized by performing biochemical index detection and liver pathological examination on the experimental mouse. The method has the beneficial effects that Balb/c inbred line mice are adopted as model animals, most inbred lines can be adopted, the repeatability is better, the cost is lower compared with rats, and the operation is simpler and more convenient. The model better conforms to the disease development process of clinical hepatitis B virus (HBV) related chronic and acute liver failure.

The invention discloses application of berberine hydrochloride shown as a formula (I) in preparation of a medicine used for preventing and/or treating acute hepatic failure and belongs to the field of biological medicine. According to the invention, the prevention and treatment effects of berberine hydrochloride to acute hepatic failure are inspected by building a D-galactosamine and LPS (lipopolysaccharide)-induced acute hepatic failure mouse animal model; results of experimental analysis in biology, pharmacology and molecular biology show that the effects of obviously reducing transaminase, inhibiting oxidative stress injury and inhibiting release of inflammatory factors can be realized by virtue of administration of berberine hydrochloride, and the death rate of acute hepatic failure mice can be obviously reduced, so that research results of the invention show that berberine hydrochloride can be applied to preparation of the medicine used for preventing and/or treating the acute hepatic failure. The formula (I) is described in the specification.

The invention discloses a traditional Chinese medicine composition for treating chronic and acute liver failure enterogenic endotoxemia. The composition is prepared from, by weight, 20-23 parts of rhubarb, 10-20 parts of cortex magnoliae officinalis, 10-20 parts of fructus aurantii immaturus, 20-40 parts of red peony roots, 10-20 parts of fructus mume, 20-40 parts of dandelions and 10-15 parts of coptidis rhizomes. The traditional Chinese medicine composition can be prepared into an enema through the method including the steps that all the raw materials are evenly mixed, water is added and gets over the medicine surface, the materials are soaked for 20-40 min and decocted for two to five times, decoction solutions obtained each time are combined, and the enema is obtained. The traditional Chinese medicine enema can be used for treating enterogenic endotoxemia, protecting intestinal mucosa, improving intestinal flora and facilitating disease recovery, the length of stay can be shortened, and medical cost is reduced.

The present invention derives from the unexpected finding that necroptosis is a novel biomarker and target for therapy in patients with liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). RIPK1, MLKL or RIPK3 can be detected and quantified in serum or plasma, and used as a biomarker for outcome in ACLF and other diseases involving aberrant necroptosis. By antagonising RIPK1, MLKL or RIPK3 many of the unwanted consequences or symptoms of acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL and RIPK3 that may be used in the treatment or prevention of ACLF. The present invention utilises these findings to identify and provide antagonists of RIPK1, MLKL or RIPK3 that may be used in the treatment or prevention of aberrant necroptosis in the kidney, brain, liver or other organ of the body.

The invention discloses a pharmaceutical use of argininyl fructosy glucose, and belongs to the field of research and development of pharmaceutical products. The pharmaceutical use refers to application of the argininyl fructosy glucose, as an active ingredient, in preparation of drugs for treating or preventing acute hepatic failure. The acute hepatic failure is oxidative stress injury caused by the combination of lipopolysaccharide and D-galactosamine, liver cells are protected from injuries, and apoptosis caused by LPS/D-GalN is reduced. The purity of the argininyl fructosy glucose is 80-99.99%. The argininyl fructosy glucose is applied to prevention or treatment of the acute hepatic failure for the first time, so that a new raw material is provided for the preparation of the drugs for the acute hepatic failure, and a new method is also provided for the prevention and treatment of the acute liver failure.

The invention discloses an application of a schisandra chinensis monomer compound in preparation of drugs for prevention and treatment of hepatotoxicity caused by acetaminophen (APAP), wherein the schisandra chinensis monomer compound is deoxyschizandrin, schisandrin C, schisandrin or schisantherin a. Experiment results show that: with the schisandra chinensis monomer compound, the ALT content and the AST content in the APAP-induced liver injury animal model can be significantly reduced, consumption of glutathione in liver cells can be inhibited, the liver cell necrosis degree can be effectively improved, and the schisandra chinensis monomer compound provides significant treatment and protection effects for hepatotoxicity symptoms caused by APAP.

The invention provides application of rhIL-1Ra in preparing medicaments for treating acute liver failure. Compared with a control group, the rhIL-1Ra can obviously inhibit the activity of alanine aminotransferase and aspartate aminotransferase in serum, the death of liver cells is reduced, and the proliferation of the liver cells is promoted, so that the rhIL-1Ra has obvious therapeutic effects ofprotecting liver injury and promoting liver regeneration. In addition, the rhIL-1Ra inhibits apoptosis mediated by caspase-3, caspase-8 and caspase-9 activation in liver tissue by decreasing mitochondrial cytochrome c release. In summary, the rhIL-1Ra provides a strategy for the preparation of candidate drugs capable of reducing hepatocyte apoptosis for the treatment of APAP-induced acute liver failure and liver injury.